Scholars@Duke
Diane L. Reidy-Lagunes

Diane L. Reidy-Lagunes

Professor of Medicine
Medicine, Medical Oncology
Office hours 9:00 am - 5:00 pm  

Scholarly Works

Consensus Guideline for the Management of Malignant Gastrointestinal Obstruction in Patients with Peritoneal Surface Malignancies.

Journal article Ann Surg Oncol · June 2026 BACKGROUND: Malignant gastrointestinal obstruction (MGIO), a frequent complication of peritoneal surface malignancies (PSM), often portends a poor prognosis. The lack of high-quality evidence on optimal management strategies necessitated a national consens ... Full text Link to item Cite

Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases.

Journal article Ann Surg Oncol · June 2026 BACKGROUND: The peritoneum is a common site of metastases from colorectal cancer (CRC), yet controversy exists regarding optimal treatment strategies. These guidelines describe the results of a national consensus addressing the management of CRC with perit ... Full text Link to item Cite

Clinical Validity of NETest2.0® in Surveillance of Neuroendocrine Tumor Patients: Evidence from a NET Registry Study (NCT02270567).

Journal article Cancers (Basel) · May 1, 2026 Background/Objectives: The NETest is a blood-based, machine learning-enhanced multigene transcript assay designed to detect and monitor neuroendocrine tumors (NETs). This study evaluated the accuracy of the recently validated NETest2.0® (2025) to (1) detec ... Full text Link to item Cite

Automated Portal-Enabled Elicitation of Health-Related Patient Values in Solid Tumor Oncology: Feasibility and Patient Characteristics Associated With Patient Response.

Journal article JCO Oncol Pract · March 2026 PURPOSE: Patient portals increase communication, but little is known about response rates or patient characteristics associated with patient responses to portal-enabled questionnaires about health-related values (HRVs). METHODS: We tested feasibility of se ... Full text Link to item Cite

Dual pancreatic carcinomas: clonally related or independent primaries?

Journal article NPJ Precis Oncol · February 8, 2026 Dual pancreatic cancers, either synchronous or metachronous in presentation, are a rare occurrence. It remains unclear if these lesions are clonally related or independently occurring primary malignancies. Herein we present a cohort (N = 22) with dual panc ... Full text Link to item Cite

Safety and efficacy of Yttrium-90 transarterial radioembolization of neuroendocrine liver metastasis - A retrospective single-institution study.

Journal article Eur J Radiol · February 2026 PURPOSE: To determine safety and efficacy of Yttrium-90 transarterial radioembolization (TARE) for neuroendocrine liver metastases (NLM). MATERIALS AND METHODS: Retrospective analysis of 39 patients [17 male; mean age 65.5 years (SD ± 12.25)] who underwent ... Full text Link to item Cite

Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC.

Journal article J Transl Med · December 24, 2025 BACKGROUND: Pancreatic acinar cell carcinoma (ACC) is a rare primary neoplasm of acinar cell origin. Histologically, it can present as pure ACC or mixed with neuroendocrine or ductal differentiation. We studied whether ACC shared genomic similarities with ... Full text Link to item Cite

Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.

Journal article JCO Precis Oncol · November 2025 PURPOSE: Delta-like ligand 3 (DLL3) is an emerging target across neuroendocrine cancers, but remains underexplored in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs), including poorly differentiated gastroenteropancreatic neuroendocrine carcinom ... Full text Link to item Cite

Consensus guideline for the management of colorectal cancer with peritoneal metastases.

Journal article Cancer · July 1, 2025 The peritoneum is a common site of metastases from colorectal cancer (CRC), yet controversy exists regarding optimal treatment strategies. These guidelines describe the results of a national consensus addressing the management of CRC with peritoneal metast ... Full text Link to item Cite

Landscape of functional DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs).

Conference Journal of Clinical Oncology · June 2025 4146Background: Delta-like ligand 3 (DLL3) is an emerging target in multiple neuroendocrine cancers including small cell lung ... Full text Cite

Clinicopathological features of colorectal cancer in adolescents and young adults (AYA) at a tertiary referral centre in Nigeria.

Conference Journal of Clinical Oncology · June 2025 3629Background: Colorectal cancer (CRC) is traditionally considered a disease of older adults; however, its incidence among A ... Full text Cite

Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma.

Journal article Ann Surg Oncol · April 2025 BACKGROUND: Randomized data suggest improved survival with adjuvant chemotherapy for biliary tract cancers; however, subset analyses of intrahepatic cholangiocarcinoma (IHC) show limited survival benefit. This study evaluated the impact of adjuvant chemoth ... Full text Link to item Cite

Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy.

Journal article J Natl Cancer Inst · February 1, 2025 BACKGROUND: Hepatic artery infusion of chemotherapy has demonstrated disease control and suggested improvement in overall survival in intrahepatic cholangiocarcinoma. We report herein the long-term results and role of molecular alterations of a phase II cl ... Full text Link to item Cite

Alpelisib for Long-term Management of Tumor-Induced Hypoglycemia.

Journal article AACE Endocrinol Diabetes · 2025 BACKGROUND/OBJECTIVE: Tumor-induced hypoglycemia (TIH) is a rare and often fatal complication of cancers that produce or induce secretion of hormones such as insulin, insulin-like growth factor 2, and proinsulin. We present a case series describing the eff ... Full text Link to item Cite

Loss of DAXX/ATRX Protein Expression Results in Ischemia Resistance and Radiation Sensitivity in Pancreatic Neuroendocrine Tumor Cells and Is Associated with Improved Response to Trans-Arterial Radioembolization.

Journal article Neuroendocrinology · 2025 INTRODUCTION: Metastatic liver pancreatic neuroendocrine tumors (PNETs) can be treated with ischemia-based trans-arterial embolization/trans-arterial chemo-embolization or radiation-based trans-arterial radioembolization (TARE). Guidelines for treatment se ... Full text Link to item Cite

A review of mitotane in the management of adrenocortical cancer.

Journal article Oncologist · September 6, 2024 IMPORTANCE: Mitotane (Lysodren, o,p'-DDD [1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane)] is currently the only United States Food and Drug Administration and European Medicines Agency-approved product for the treatment of adrenocortical carcino ... Full text Link to item Cite

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.

Journal article Endocr Relat Cancer · September 1, 2024 Prospective data are lacking on early somatostatin analog (SSA) therapy in bronchopulmonary neuroendocrine tumors (BP-NETs; typical carcinoids and atypical carcinoids (TCs and ACs)). SPINET (EudraCT: 2015-004992-62; NCT02683941) was a phase III, double-bli ... Full text Link to item Cite

Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors.

Journal article Ann Surg Oncol · April 2024 BACKGROUND: The benefit of primary tumor resection in distant metastatic small bowel neuroendocrine tumors (SBNETs) is controversial, with treatment-based morbidity not well-defined. We aimed to determine the impact of primary tumor resection on developmen ... Full text Link to item Cite

Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms.

Journal article Endocr Relat Cancer · April 1, 2024 In advanced pancreatic neuroendocrine neoplasms (PanNEN), there are little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients w ... Full text Link to item Cite

Abstract C104: Dual primary pancreas cancers – Related or independent lesions?

Conference Cancer Research · January 16, 2024 AbstractBackground: Not infrequently, an apparent second pancreas ductal adenocarcinoma (PDAC) is identified either synchronously or metachronously. To date, it remains unclear whether these individual PDACs ... Full text Cite

Early-Onset Pancreatic Neuroendocrine Tumors: Clinical Presentation, Pathology Features, and Oncological Outcomes.

Journal article Ann Surg · January 1, 2024 BACKGROUND: Early-Onset (EO) pancreatic neuroendocrine tumor (PanNET) is a rare disease, but whether it is clinically different from late-onset (LO) PanNET is unknown. Our study aimed to evaluate clinical differences and disease outcomes between EO-PanNET ... Full text Link to item Cite

Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trials.

Journal article Eur Radiol · December 2023 BACKGROUND: Several barriers hamper recruitment of diverse patient populations in multicenter clinical trials which determine efficacy of new systemic cancer therapies. PURPOSE: We assessed if quantitative analysis of computed tomography (CT) scans of meta ... Full text Link to item Cite

A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors

Journal article Endocrine Related Cancer · November 1, 2023 We assessed the efficacy and safety of combining bevacizumab with temsirolimus in patients with advanced extra-pancreatic neuroendocrine tumors. This NCI-sponsored multicenter, open-label, phase II study (NCT01010126) enrolled patients with advanced, recur ... Full text Cite

Recurring Pancreatic Neuroendocrine Tumor: Timing and Pattern of Recurrence and Current Treatment.

Journal article Ann Surg · November 1, 2023 OBJECTIVE: The objective of this study was to describe the pattern of recurrence, treatments received, as well the oncological outcomes, of pancreatic neuroendocrine tumors (PanNETs) following curative surgery. BACKGROUND: PanNETs recur in 10% to 15% of ca ... Full text Link to item Cite

Hepatic Hilar Block as an Adjunct to Transarterial Embolization of Neuroendocrine Tumors: A Retrospective Review of Safety and Efficacy.

Journal article Cancers (Basel) · October 29, 2023 PURPOSE: This study investigates whether hepatic hilar nerve blocks (HHNB) provide safe, effective analgesia in patients with neuroendocrine tumors (NET) treated with transarterial embolization (TAE). METHODS: The retrospective study included all NETs trea ... Full text Link to item Cite

Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade.

Journal article Nat Med · October 2023 Metastatic and localized mismatch repair-deficient (dMMR) tumors are exquisitely sensitive to immune checkpoint blockade (ICB). The ability of ICB to prevent dMMR malignant or pre-malignant neoplasia development in patients with Lynch syndrome (LS) is unkn ... Full text Link to item Cite

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.

Journal article J Natl Cancer Inst · September 7, 2023 Important progress has been made over the last decade in the classification, imaging, and treatment of neuroendocrine neoplasm (NENs), with several new agents approved for use. Although the treatment options available for patients with well-differentiated ... Full text Link to item Cite

Patient Portals to Elicit Essential Patient-Reported Elements of Communication Supporting Person-Centered Oncologic Care: A Pilot Study of the PERSON Approach.

Journal article JCO Clin Cancer Inform · September 2023 PURPOSE: Patient portal technology offers important new opportunities to support person-centered clinician-patient communication. METHODS: Questionnaires relating to understanding of illness and treatment intent were sent quarterly via portal to all patien ... Full text Link to item Cite

Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.

Journal article Br J Cancer · August 2023 BACKGROUND: To date, single-agent immune checkpoint inhibitor (CPI) therapy has proven to be ineffective against biomarker-unselected extrapulmonary poorly differentiated neuroendocrine carcinomas (EP-PDNECs). The efficacy of CPI in combination with chemot ... Full text Link to item Cite

Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review.

Journal article Clin Genitourin Cancer · June 2023 BACKGROUND: Primary urinary neuroendocrine neoplasms (U-NENs) are extremely rare thus optimal treatment is unknown. Grading and treatment are typically extrapolated from other primary sites. Since 2010, the clinical landscape for NENs has changed substanti ... Full text Link to item Cite

Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumors.

Journal article J Nucl Med · April 2023 Reliable biomarkers for neuroendocrine tumor (NET) management during peptide receptor radionuclide therapy (PRRT) are lacking. We validated the role of 2 circulating biomarkers: the PRRT prediction quotient (PPQ) as a predictive marker for response and the ... Full text Link to item Cite

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).

Journal article J Clin Oncol · March 1, 2023 PURPOSE: Patients with advanced pancreatic neuroendocrine tumors (NETs) have few treatment options that yield objective responses. Retrospective and small prospective studies suggest that capecitabine and temozolomide are associated with high response rate ... Full text Link to item Cite

Association Between Remote Monitoring and Acute Care Visits in High-Risk Patients Initiating Intravenous Antineoplastic Therapy.

Journal article JCO Oncol Pract · December 2022 PURPOSE: Traditional oncology care models have not effectively identified and managed at-risk patients to prevent acute care. A next step is to harness advances in technology to enable patients to report symptoms any time, enabling digital hovering-intensi ... Full text Link to item Cite

A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.

Journal article JCO Oncol Pract · September 2022 PURPOSE: Somatostatin analogs octreotide long-acting release (octLAR) and lanreotide are equally acceptable in National Comprehensive Cancer Network guidelines for neuroendocrine tumors (NETs). Lanreotide is more expensive and given by deep subcutaneous in ... Full text Link to item Cite

Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.

Journal article Oncologist · May 6, 2022 BACKGROUND: Total neoadjuvant therapy (TNT) improves tumor response in locally advanced rectal cancer (LARC) patients compared to neoadjuvant chemoradiotherapy alone. The effect of TNT on patient survival has not been fully investigated. MATERIALS AND METH ... Full text Link to item Cite

Analysis of a Remote Monitoring Program for Symptoms Among Adults With Cancer Receiving Antineoplastic Therapy.

Journal article JAMA Netw Open · March 1, 2022 IMPORTANCE: Electronic patient-reported outcomes (ePROs) may have the potential to improve cancer care delivery by enhancing patient quality of life, reducing acute care visits, and extending overall survival. However, the optimal cadence of ePRO assessmen ... Full text Link to item Cite

Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.

Conference Journal of Clinical Oncology · February 1, 2022 TPS514 Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which represent approximately 70% of NETs, frequently develop metastatic disease with limited treatment options. Current standard therapies for well-diff ... Full text Cite

Early-onset well differentiated pancreatic neuroendocrine tumors: Clinical presentation, pathologic features, and oncological outcomes.

Conference Journal of Clinical Oncology · February 1, 2022 507 Background: Young onset of several gastrointestinal cancers is associated with more advanced disease and poor oncological outcomes, however, this association has not been fully investigated for well differentiated pancreatic ... Full text Cite

Treatment response and clinical outcomes of neuroendocrine neoplasms treated with immune checkpoint inhibitors: A single-institution experience.

Conference Journal of Clinical Oncology · February 1, 2022 506 Background: Immune checkpoint inhibitors (ICIs) have antitumor activity in some solid tumors, however a role for ICI’s in the treatment of neuroendocrine neoplasms (NENs) is uncertain. We analyzed response and outcomes of NEN ... Full text Cite

An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans.

Journal article Eur J Cancer · January 2022 BACKGROUND & AIMS: Quantitative analysis of computed tomography (CT) scans of patients with metastatic colorectal cancer (mCRC) can identify imaging signatures that predict overall survival (OS). METHODS: We retrospectively analysed CT images from 1584 mCR ... Full text Link to item Cite

Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE.

Journal article Neuroendocrinology · 2022 INTRODUCTION: Lutetium-177 (177Lu)-DOTATATE received FDA approval in 2018 to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (NETs). Little data are available on response and outcomes for well-differentiated (WD) high-grad ... Full text Link to item Cite

A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers.

Journal article J Natl Cancer Inst · November 29, 2021 BACKGROUND: The causative factors for the recent increase in early-onset colorectal cancer (EO-CRC) incidence are unknown. We sought to determine if early-onset disease is clinically or genomically distinct from average-onset colorectal cancer (AO-CRC). ME ... Full text Link to item Cite

Severe Acute Respiratory Syndrome Coronavirus 2 Surveillance and Exposure in the Perioperative Setting With Universal Testing and Personal Protective Equipment Policies.

Journal article Clin Infect Dis · November 2, 2021 BACKGROUND: New York City (NYC) experienced a surge of coronavirus disease 2019 (COVID-19) cases in March and April 2020. Since then, universal polymerase chain reaction (PCR)-based surveillance testing and personal protective equipment (PPE) measures are ... Full text Link to item Cite

Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.

Journal article Oncologist · November 2021 BACKGROUND: Grade 3 gastroenteropancreatic neuroendocrine neoplasms (G3 GEPNENs) are often aggressive, and the optimal treatment is unclear for this subgroup of neuroendocrine neoplasms (NENs). Temozolomide (TEM)-based regimens have been increasingly used ... Full text Link to item Cite

Oncology Patients' Perspectives on Remote Patient Monitoring for COVID-19.

Journal article JCO Oncol Pract · September 2021 PURPOSE: Oncology patients are vulnerable to adverse outcomes associated with COVID-19, and clinical deterioration must be identified early. Several institutions launched remote patient monitoring programs (RPMPs) to care for patients with COVID-19. We des ... Full text Link to item Cite

Cancer Clinical Trials in Africa-An Untapped Opportunity: Recommendations From AORTIC 2019 Conference Special Interest Group in Clinical Trials.

Journal article JCO Glob Oncol · August 2021 Cancer is now a formidable health care burden in sub-Saharan Africa (SSA) due to lifestyle westernization and longer life expectancy. The exponential increase in cancer incidence coupled with high mortality rate is not comparable with that seen in westerni ... Full text Link to item Cite

Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Journal article J Natl Compr Canc Netw · July 28, 2021 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paragangliom ... Full text Link to item Cite

Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19.

Journal article J Natl Cancer Inst · July 1, 2021 The clinical spectrum of coronavirus disease 2019 (COVID-19) is still not fully understood. Cancer patients are uniquely vulnerable to COVID-19, and many have been or will be infected. Although an unfortunate minority will die from the infection, most will ... Full text Link to item Cite

Quantitative Computed Tomography Image Analysis to Predict Pancreatic Neuroendocrine Tumor Grade.

Journal article JCO Clin Cancer Inform · June 2021 PURPOSE: The therapeutic management of pancreatic neuroendocrine tumors (PanNETs) is based on pathological tumor grade assessment. A noninvasive imaging method to grade tumors would facilitate treatment selection. This study evaluated the ability of quanti ... Full text Link to item Cite

Use of remote patient monitoring in the care of COVID-positive patients in oncology.

Conference Journal of Clinical Oncology · May 20, 2021 1554 Background: Cancer patients face an increased risk of developing acute complications from COVID-19. Remote monitoring can help with the critical need for early detection of symptoms among those diagnosed with COVID-19, enabl ... Full text Cite

Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part B (pembrolizumab + chemotherapy).

Conference Journal of Clinical Oncology · May 20, 2021 4148 Background: The efficacy of immune checkpoint inhibitor (CPI) therapy has not been established in extrapulmonary poorly differentiated neuroendocrine carcinomas (EP-PDNECs). In small cell lung cancer, CPI therapy is approved ... Full text Cite

Oncology patients’ perspectives on remote patient monitoring for COVID-19.

Conference Journal of Clinical Oncology · May 20, 2021 1504 Background: Oncology patients are particularly vulnerable to adverse outcomes from COVID-19 and require careful monitoring to identify early deterioration and render higher level care when indicated. Several institutions lau ... Full text Cite

Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well differentiated neuroendocrine tumors (WDNETs).

Conference Journal of Clinical Oncology · May 20, 2021 e16204 Background: The somatostatin analogs (SSAs) octreotide LAR and lanreotide are equally acceptable in the NCCN guidelines to treat WDNETs. Average Sales Price for 1 year of lanreotide at 120mg is $106,802 versus $53,471 for ... Full text Cite

Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.

Journal article Clin Cancer Res · April 15, 2021 PURPOSE: Immune checkpoint inhibition (ICI) alone is not active in mismatch repair-proficient (MMR-P) metastatic colorectal cancer (mCRC), nor does radiotherapy alone result in objective systemic benefit. However, combined radiotherapy plus ICI can induce ... Full text Link to item Cite

Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors.

Journal article Endocr Relat Cancer · April 2021 The mammalian target of rapamycin inhibitor everolimus is an established therapy for well-differentiated (WD) foregut neuroendocrine tumors (NETs). Pre-clinical data demonstrates a potential synergistic role for cyclin dependent kinase 4/6 inhibition and e ... Full text Link to item Cite

Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity.

Journal article Pancreatology · April 2021 BACKGROUND: /Objectives: Pancreatic adenocarcinoma (PDAC) metastatic to the leptomeninges is a rare and lethal event. Leptomeningeal disease (LMD) research is limited in PDAC, and insights into clinical descriptors, possible disease predictors, and treatme ... Full text Link to item Cite

Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma.

Journal article Clin Cancer Res · March 1, 2021 PURPOSE: The prevalence and clinical characteristics of small bowel adenocarcinomas (SBA) in the setting of Lynch syndrome have not been well studied. We characterized SBA according to DNA mismatch repair and/or microsatellite instability (MMR/MSI) and ger ... Full text Link to item Cite

Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms.

Journal article Pancreas · February 1, 2021 OBJECTIVES: Pancreatic neuroendocrine neoplasms include well-differentiated tumors (PanNETs) and poorly differentiated carcinomas (PanNECs). Previous reports suggested a role for platinum-based therapy largely in PanNEC. We sought to investigate the role o ... Full text Link to item Cite

Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance.

Journal article J Natl Compr Canc Netw · February 2021 Lynch syndrome is a heritable cancer syndrome caused by a heterozygous germline mutation in DNA mismatch repair (MMR) genes. MMR-deficient (dMMR) tumors are particularly sensitive to immune checkpoint inhibitors, an effect attributed to the higher mutation ... Full text Link to item Cite

Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE.

Conference Journal of Clinical Oncology · January 20, 2021 368 Background: 177Lu-DOTATATE is an approved therapy for somatostatin receptor (sstr) positive gastroenteropancreatic neuroendocrine tumors (NETs). There are little data available on response and outcomes fo ... Full text Cite

Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy.

Journal article Eur J Nucl Med Mol Imaging · December 2020 PURPOSE: Paired imaging/therapy with radiolabeled somatostatin receptor (SSTR) antagonists is a novel approach in neuroendocrine tumors (NETs). The aim of this study was to compare tumor uptake of 68Ga-DOTA-JR11 and 177Lu-satoreotide tetraxetan (177Lu-DOTA ... Full text Link to item Cite

Predicting malignancy in patients with adrenal tumors using 18 F-FDG-PET/CT SUVmax.

Journal article J Surg Oncol · December 2020 BACKGROUND AND OBJECTIVES: 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG-PET/CT) parameters may help distinguish malignant from benign adrenal tumors, but few have been externally validated or determined based on defini ... Full text Link to item Cite

NANETS / SNMMI consensus statement on patient selection and appropriate use of 177 Lu- DOTATATE peptide receptor radionuclide therapy

Journal article Chinese Journal of Nuclear Medicine and Molecular Imaging · November 25, 2020 Full text Cite

Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors.

Journal article Pancreas · October 2020 Patients with neuroendocrine tumors (NETs) and carcinoid syndrome experience diarrhea that can have a debilitating effect on quality of life. Diarrhea also may develop in response to other hormonal syndromes associated with NETs, surgical complications, me ... Full text Link to item Cite

InSight Care Pilot Program: Redefining Seeing a Patient.

Journal article JCO Oncol Pract · October 2020 PURPOSE: Early detection and management of symptoms in patients with cancer improves outcomes. However, the optimal approach to symptom monitoring and management is unknown. InSight Care is a mobile health intervention that captures symptom data and facili ... Full text Link to item Cite

Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review.

Journal article Palliat Support Care · October 2020 OBJECTIVE: Symptoms of depression and anxiety are common in neuroendocrine tumor (NET), yet controversy exists over whether serotonin-mediated antidepressants (SAs) are safe in this population. We sought to address this knowledge gap. METHOD: Following PRI ... Full text Link to item Cite

Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors.

Journal article Cancer · August 15, 2020 BACKGROUND: Antiangiogenic-targeting agents have low response rates in patients with nonpancreatic neuroendocrine tumors (NETs). Nintedanib is an oral antiangiogenic agent that has inhibitory effects on the fibroblast growth factor receptor, which is highl ... Full text Link to item Cite

Abstract LB-003: OncoMatch: Unbiased, quantitative assessment of cancer model fidelity for drug sensitivity and mechanism of action elucidation

Conference Cancer Research · August 15, 2020 AbstractQuantitative metrics to objectively assess the fidelity of cancer models, such as cell lines, organoids, or patient-derived xenografts (PDXs), remain elusive, with histological criteria or the presen ... Full text Cite

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors.

Journal article Pancreas · August 2020 This article is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management of pancreatic neuroendocrine tumors from July 19 to 20, 2018. The guidelines panel consisted of medical oncologists, pathologists, ... Full text Link to item Cite

Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.

Journal article Clin Cancer Res · July 1, 2020 PURPOSE: Evaluate response of mismatch repair-deficient (dMMR) rectal cancer to neoadjuvant chemotherapy. EXPERIMENTAL DESIGN: dMMR rectal tumors at Memorial Sloan Kettering Cancer Center (New York, NY) were retrospectively reviewed for characteristics, tr ... Full text Link to item Cite

Lack of Availability and Efficacy of Phase I and Basket Trials for Patients With Gastrointestinal Cancers.

Journal article J Natl Cancer Inst · May 1, 2020 In the modern era of targeted and immune-based therapies, investigator and patient expectations of availability and efficacy in phase I trials have increased. We assessed availability of, and benefit from, early drug development trials, specifically in pat ... Full text Link to item Cite

Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

Journal article JAMA Oncol · January 1, 2020 IMPORTANCE: Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with a median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients. OBJECTIVE: To ... Full text Link to item Cite

PD-1 Blockade in Advanced Adrenocortical Carcinoma.

Journal article J Clin Oncol · January 1, 2020 PURPOSE: Adrenocortical carcinomas (ACC) are rare and aggressive malignancies with limited treatment options. This study was undertaken to evaluate the immunogenicity of ACC. PATIENTS AND METHODS: Patients with advanced ACC were enrolled in a phase II stud ... Full text Link to item Cite

A Modern Miliary Infiltrate

Conference AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE · 2020 Link to item Cite

Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.

Journal article Clin Cancer Res · December 1, 2019 PURPOSE: Radiolabeled somatostatin receptor 2 (SSTR2) antagonists have shown higher tumor uptake and tumor-to-organ ratios than somatostatin agonists in preclinical models of neuroendocrine tumors (NETs). We performed a phase I study to evaluate the safety ... Full text Link to item Cite

Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.

Journal article Curr Treat Options Oncol · November 27, 2019 Over the years, there have been significant advances in systemic treatments for metastatic pancreatic neuroendocrine tumors (panNETs). Despite these advancements, uncertainty remains regarding how to best sequence available therapies. For well-differentiat ... Full text Link to item Cite

Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short-term outcomes.

Journal article Colorectal Dis · October 2019 AIM: Significant recent changes in management of locally advanced rectal cancer (LARC) include preoperative staging, use of extended neoadjuvant therapies and minimally invasive surgery (MIS). This study was aimed at characterizing these changes and associ ... Full text Link to item Cite

Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer.

Journal article Clin Colorectal Cancer · September 2019 BACKGROUND: Initial treatment with either neoadjuvant chemoradiation (CRT) or induction FOLFOX (5-Fluorouracil, leucovorin, and oxaliplatin) chemotherapy followed by CRT is considered standard treatment for locally advanced rectal cancer. We compared patie ... Full text Link to item Cite

Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway.

Journal article Mol Oncol · August 2019 Solid pseudopapillary neoplasms (SPNs) are rare and relatively indolent tumors of the pancreas. While primary SPNs can be surgically resected, there are currently no therapies available for patients with advanced stage disease. Given that these tumors freq ... Full text Link to item Cite

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma.

Journal article Invest New Drugs · August 2019 Background Adrenal cortical carcinoma (ACC) is a rare cancer with treatment options of limited efficacy, and poor prognosis if metastatic. AT-101 is a more potent inhibitor of B cell lymphoma 2 family apoptosis-related proteins than its racemic form, gossy ... Full text Link to item Cite

Giving Voice to Patient Values Throughout Cancer: A Novel Nurse-Led Intervention.

Conference J Pain Symptom Manage · July 2019 CONTEXT: Optimal advance care planning allows patients to articulate their values as a touchstone for medical decision making. Ideally, this occurs when patients are clinically stable, and with opportunities for iteration as the clinical situation unfolds. ... Full text Link to item Cite

A framework for building a clinically relevant risk model.

Conference Journal of Clinical Oncology · May 20, 2019 6554 Background: Acute care accounts for half of cancer expenditures and is a measure of poor quality care. Identifying patients at high risk for emergency department (ED) visits enables institutions to target resources to those ... Full text Cite

Risk stratification and daily symptom monitoring for oncology patients.

Conference Journal of Clinical Oncology · May 20, 2019 6535 Background: Monitoring and managing patient reported outcomes (PROs) has been recommended for oncology patients on active treatment but can be time and resource intensive. Identifying patients likely to benefit and the optim ... Full text Cite

Benefit of early-phase targeted, basket, and immune-based trials for patients with chemorefractory gastrointestinal (GI) cancers.

Conference Journal of Clinical Oncology · May 20, 2019 e15700 Background: Historically, phase I trials were designed to establish phase II tolerable doses of new drugs. Efficacy concerns were secondary. In the modern era of targeted and immune-based therapies, investigator and patien ... Full text Cite

Characterization and clinical outcomes of mismatch repair deficient (dMMR) small bowel adenocarcinoma (SBA).

Conference Journal of Clinical Oncology · May 20, 2019 1511 Background: SBA is a rare cancer known to be associated with Lynch syndrome (LS). The prevalence, tumor characteristics, and clinical course of SBAs in the setting of LS is not well understood. We sought to characterize SBA ... Full text Cite

Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.

Conference Journal of Clinical Oncology · May 20, 2019 4112 Background: Adrenocortical carcinomas (ACC) are rare and aggressive. Treatment options are limited and marked by poor efficacy and substantial toxicity. In this phase II single-center study, the efficacy and safety of pembro ... Full text Cite

Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.

Journal article HPB (Oxford) · May 2019 BACKGROUND: Serum Chromogranin A (CgA) is widely used as a biomarker for pancreatic neuroendocrine tumors (PanNETs). The aim of this study was to investigate the value of CgA as a diagnostic and prognostic marker for well-differentiated PanNETs. METHODS: P ... Full text Link to item Cite

Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors.

Journal article Eur J Nucl Med Mol Imaging · March 2019 PURPOSE: Somatostatin receptor antagonists have shown promise for imaging neuroendocrine tumors (NETs) in preclinical studies, but clinical data is still very limited. In this study, we assess the feasibility of using the novel somatostatin antagonist 68Ga ... Full text Link to item Cite

Predictors of treatment response in colorectal high-grade neuroendocrine carcinomas (HGNEC): A single institution experience.

Conference Journal of Clinical Oncology · February 1, 2019 690 Background: Colorectal high-grade neuroendocrine carcinomas (HGNEC) are aggressive tumors; treatment options consist of cis/carboplatin and 5FU-based chemotherapy. To date, choice of systemic therapy and sequencing of these d ... Full text Cite

Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone).

Conference Journal of Clinical Oncology · February 1, 2019 363 Background: Immune checkpoint inhibitor (CPI) efficacy has not been established in extrapulmonary poorly-differentiated neuroendocrine carcinomas (EP-PDNECs). In small cell lung cancer, promising antitumor activity of CPI led ... Full text Cite

Outcomes after cessation of therapy with alkylating agents (AA) for pancreatic neuroendocrine tumors (panNETs).

Conference Journal of Clinical Oncology · February 1, 2019 394 Background: There are several therapies now available for panNETs, raising concern that treatment-related toxicity, namely myelosuppression, may preclude use of all treatments. AA are an effective therapy in panNETs, but can ... Full text Cite

Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.

Conference Journal of Clinical Oncology · February 1, 2019 321 Background: G3 NENs are aggressive, and optimal systemic treatment is unclear. Temozolomide (TEM)-based regimens have been used to treat grade 1-2 NETs, but their efficacy in G3 NENs (Ki-67 > 20%) remains undetermined. Aim ... Full text Cite

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.

Journal article J Clin Oncol · February 1, 2019 PURPOSE: Microsatellite instability (MSI) and/or mismatch repair deficiency (MMR-D) testing has traditionally been performed in patients with colorectal (CRC) and endometrial cancer (EC) to screen for Lynch syndrome (LS)-associated cancer predisposition. T ... Full text Link to item Cite

Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.

Journal article PLoS One · 2019 The clinical significance of BRAF alterations in well-differentiated (WD) metastatic pancreatic neuroendocrine tumor (panNET) is unknown, but BRAF-mutated panNET could represent a subset characterized by an identifiable and clinically actionable driver. Fo ... Full text Link to item Cite

Employing electronic health record data to predict risk of ED visits for new patients.

Conference Journal of Clinical Oncology · December 1, 2018 144 Background: Acute care accounts for half of cancer expenditures and is a measure of poor quality care. Identifying patients at high risk for ED visits enables institutions to target symptom management resources to those most ... Full text Cite

DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression.

Conference J Vasc Interv Radiol · November 2018 PURPOSE: To identify common gene mutations in patients with neuroendocrine liver metastases (NLM) undergoing transarterial embolization (TAE) and establish relationship between these mutations and response to TAE. MATERIALS AND METHODS: Patients (n = 51; m ... Full text Link to item Cite

Communication lapses and navigation needs for non-English-speaking patients: An MSK Patient and Family Advisory Council and Immigrant Health and Cancer Disparities initiative.

Conference Journal of Clinical Oncology · October 20, 2018 178 Background: In 2017, 5,939 outpatients (5%) and 1,065 inpatients (9%) treated at MSK were non-English-speaking. Given the new and varying treatment paradigms combined with the need to consider clinical trial enrollment, there ... Full text Cite

Employing electronic health record data to predict risk of emergency department visits for new patients.

Conference Journal of Clinical Oncology · October 20, 2018 314 Background: Acute care accounts for half of cancer expenditures and is a measure of poor quality care. Identifying patients at high risk for ED visits enables institutions to target symptom management resources to those most ... Full text Cite

Misery Loves Company: Presenting Symptom Clusters to Urgent Care by Patients Receiving Antineoplastic Therapy.

Journal article J Oncol Pract · August 2018 PURPOSE: The Centers for Medicare & Medicaid Services (CMS) identifies suboptimal management of treatment toxicities as a care gap and proposes the measurement of hospital performance on the basis of emergency department visits for 10 common symptoms. Curr ... Full text Link to item Cite

MENIN loss as a tissue-specific driver of tumorigenesis.

Journal article Mol Cell Endocrinol · July 5, 2018 The MEN1 gene encodes MENIN, a tumor suppressor that plays a role in multiple cellular processes. Germline and somatic mutations in MEN1 have been identified in hereditary and sporadic tumors of neuroendocrine origins suggesting context-specific functions. ... Full text Link to item Cite

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.

Journal article Nat Genet · July 2018 We introduce and validate a new precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients. Compounds are prioritized on the basis of their ability to invert the concerted activit ... Full text Link to item Cite

Abstract 3735: Somatostatin receptor-based imaging and treatment of murine pancreatic neuroendocrine tumors induced by MEN1-loss

Conference Cancer Research · July 1, 2018 AbstractBackground: Somatostatin receptor ligands are used for the detection and treatment of neuroendocrine tumors. Mutations of MEN1 are frequently observed in human pancreatic neuroendocrine tumors (PanNE ... Full text Cite

Abstract 3656: Detecting MSI in plasma: Implications for early detection of lynch associated tumors

Conference Cancer Research · July 1, 2018 AbstractLynch Syndrome (LS) is characterized by germline mutations in mismatch repair pathway genes. The increased cancer susceptibility risk in these patients and the association of these tumors with micros ... Full text Cite

Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.

Journal article JAMA Oncol · June 14, 2018 IMPORTANCE: Treatment of locally advanced rectal (LARC) cancer involves chemoradiation, surgery, and chemotherapy. The concept of total neoadjuvant therapy (TNT), in which chemoradiation and chemotherapy are administered prior to surgery, has been develope ... Full text Link to item Cite

Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?

Journal article Clin Colorectal Cancer · June 2018 PURPOSE: To assess clinical characteristics of patients with metastatic pancreas ductal adenocarcinoma (PDAC) and brain metastases (BM), and to assess somatic and germ-line molecular profiles where performed. PATIENTS AND METHODS: Patients with PDAC and BM ... Full text Link to item Cite

Antidepressants appear safe in patients with carcinoid tumor: Results of a retrospective review.

Journal article Eur J Surg Oncol · June 2018 INTRODUCTION: Patients living with neuroendocrine tumors have high rates of depression, often necessitating antidepressants, including selective serotonin reuptake inhibitors (SSRI). Neuroendocrine tumors (NETs) secrete vasoactive substances, including ser ... Full text Link to item Cite

Widespread somatic loss of heterozygosity as a possible marker of disease aggressiveness in metastatic well differentiated pancreatic neuroendocrine tumors.

Conference Journal of Clinical Oncology · February 1, 2018 275 Background: To assess the utility of molecular profiling to predict tumor biology, we performed next-generation sequencing (NGS) of metastatic well differentiated (WD) pancreatic neuroendocrine tumors (panNETs) in the routine ... Full text Cite

A phase II trial of LEE011 in combination with everolimus in the treatment of advanced well differentiated neuroendocrine tumors of foregut origin.

Conference Journal of Clinical Oncology · February 1, 2018 TPS546 Background: Changes in the retinoblastoma (Rb) tumor suppressor pathway are believed to contribute to the development of well differentiated neuroendocrine tumors (WDNETs). In the pre-clinical setting, loss or downregulati ... Full text Cite

Quantitative CT analysis for the preoperative prediction of pathologic grade in pancreatic neuroendocrine tumors

Conference Progress in Biomedical Optics and Imaging Proceedings of SPIE · January 1, 2018 Pancreatic neuroendocrine tumors (PanNETs) account for approximately 5% of all pancreatic tumors, affecting one individual per million each year.1 PanNETs are difficult to treat due to biological variability from benign to highly malignant, indo ... Full text Cite

Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.

Journal article J Nucl Med · January 2018 123I-meta-iodobenzylguanidine (123I-MIBG) imaging is currently a mainstay in the evaluation of many neuroendocrine tumors, especially neuroblastoma. 123I-MIBG imaging has several limitations that can be overcome by the use of a PET agent. 18F-meta-fluorobe ... Full text Link to item Cite

Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability.

Journal article JCO Precis Oncol · 2018 PURPOSE: We assessed the usefulness of real-time molecular profiling through next-generation sequencing (NGS) in predicting the tumor biology of advanced pancreatic neuroendocrine tumors (panNETs) and in characterizing genomic evolution. METHODS: Patients ... Full text Link to item Cite

Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case report.

Journal article Medicine (Baltimore) · December 2017 RATIONALE: Glucagonoma is an uncommon disease but it has been associated with a pattern of symptoms defined as glucagonoma syndrome. These symptoms, if promptly recognized, could help to speed up the diagnosing process. PATIENT CONCERNS: We report a case o ... Full text Link to item Cite

Biodistribution and radiation dosimetry of 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors

Conference EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · October 2017 Link to item Cite

Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.

Journal article Oncologist · September 2017 PURPOSE: Based largely on reports that predate modern reporting standards, mitotane has been considered a systemic treatment option for both hormone control and antitumor control of metastatic adrenocortical cancer (ACC), although the therapeutic window is ... Full text Link to item Cite

Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.

Journal article Int J Radiat Oncol Biol Phys · August 1, 2017 PURPOSE: To assess the impact on acute toxicity of replacing 5-fluorouracil (5-FU) with capecitabine in definitive chemoradiation for patients with anal squamous cell carcinoma (ASCC). METHODS AND MATERIALS: We retrospectively reviewed the records of 107 c ... Full text Link to item Cite

O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.

Journal article Pancreas · July 2017 OBJECTIVES: Alkylating agents have activity in well-differentiated pancreatic neuroendocrine tumors (WD panNETs). In glioblastoma multiforme, decreased activity of O-methylguanine DNA methyltransferase (MGMT) predicts response; in panNETs, MGMT relevance i ... Full text Link to item Cite

Abstract 4380: Integrative genomics analysis of metastatic colorectal cancer

Conference Cancer Research · July 1, 2017 AbstractWe performed an integrated clinical and bioinformatic analysis of colorectal cancers (CRCs) genotyped at our institution from 4/2014-7/2016 to comprehensively characterize genomic alterations in meta ... Full text Cite

Theranostic trial of well differentiated neuroendocrine tumors (NETs) with somatostatin antagonists 68Ga-OPS202 and 177Lu-OPS201.

Conference Journal of Clinical Oncology · May 20, 2017 4094 Background: Radiolabeled somatostatin receptor 2 (sstr2) antagonists have shown higher tumor uptake and tumor-to-organ ratios than agonists in preclinical models. We performed a phase I study to evaluate the safety and radia ... Full text Cite

The next generation of quality improvement at MSK: Turning chemotherapy process delays into chemo express.

Conference Journal of Clinical Oncology · May 20, 2017 e18230 Background: Chemotherapy wait times can dramatically affect patient experience. MSK’s largest outpatient facility has 76 infusion spaces and 250-300 daily visits. A retrospective review of the facility’s infusion area wait ... Full text Cite

Total neoadjuvant chemotherapy to facilitate delivery and tolerance of systemic chemotherapy and response in locally advanced rectal cancer.

Conference Journal of Clinical Oncology · May 20, 2017 3519 Background: The most common therapy for locally advanced (T3/4 or N+) rectal cancer (LARC) consists of preoperative chemoradiotherapy (chemoRT) followed by surgery and adjuvant chemotherapy. Recently, use of total neoadjuvan ... Full text Cite

Clinical and genetic determinants of ovarian metastases from colorectal cancer.

Journal article Cancer · April 1, 2017 BACKGROUND: Ovarian metastases from colorectal cancer (OM-CRC) often are unresponsive to chemotherapy and are associated with poor survival. To the authors' knowledge, the clinicopathologic and genomic predictors of OM-CRC are poorly characterized and opti ... Full text Link to item Cite

Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection.

Journal article Acta Oncol · March 2017 BACKGROUND: To assess local control, survival and conversion to resectability among locally advanced pancreatic cancer (LAPC) patients treated with induction chemotherapy (ICT) followed by chemoradiotherapy treatment using intensity-modulated radiation the ... Full text Link to item Cite

Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.

Journal article Pancreas · March 2017 OBJECTIVES: Emerging data suggest that not all grade 3 (G3) pancreatic neuroendocrine neoplasms (panNENs) behave the same; tumor differentiation may predict outcome. METHODS: Patients with G3 panNENs treated at our institution between 1999 and 2014 were id ... Full text Link to item Cite

Gene Signature Associated with Upregulation of the Wnt/β-Catenin Signaling Pathway Predicts Tumor Response to Transarterial Embolization.

Journal article J Vasc Interv Radiol · March 2017 PURPOSE: To identify gene mutations in tumors undergoing transarterial embolization and explore the relationship between gene mutations and tumor response to embolization. MATERIALS AND METHODS: This was a retrospective review that included 17 patients wit ... Full text Link to item Cite

Total neoadjuvant therapy for locally advanced rectal cancer.

Conference Journal of Clinical Oncology · February 1, 2017 662 Background: Current therapy for locally advanced rectal cancer (LARC) consists of 6 months of perioperative therapy, either with pre-operative chemo-radiotherapy (CRT) and post operative adjuvant chemotherapy (PAC) or total n ... Full text Cite

Next-generation sequencing (NGS) in pancreatic neuroendocrine tumors (panNETs): Defining differentiation and grade genetically.

Conference Journal of Clinical Oncology · February 1, 2017 291 Background: Advances in tumor sequencing technology have improved our understanding of the genetic basis of panNETs. Whole exome sequencing of well differentiated (WD) panNETs demonstrated changes in chromatin remodeling gene ... Full text Cite

Unusual Tumors of the Colon, Rectum, and Anus

Book section · January 1, 2017 Cancers of the colon, rectum, and anus account for more than 150,000 new cases in the USA each year. The overwhelming majority (approximately 97%) of these are adenocarcinomas of the colon or rectum. Of the 3% that make up the uncommon tumors, approximatel ... Full text Cite

Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies.

Journal article J Surg Oncol · November 2016 BACKGROUND AND OBJECTIVES: To evaluate the role of hepatic arterial infusion (HAI) in patients with metastatic colorectal cancer (mCRC) liver metastases (LM) refractory to oxaliplatin, irinotecan, and fluorouracil-based treatments. METHODS: A search identi ... Full text Link to item Cite

Cytological features contributing to the misclassification of pancreatic neuroendocrine tumors

Journal article Journal of the American Society of Cytopathology · September 1, 2016 Introduction Pancreatic neuroendocrine tumors are a diverse group of malignant neoplasms of varying biological behavior, with outcomes predicted by tumor differentiation and grade. Initial diagnosis is often made by fine-needle aspiration cytology via endo ... Full text Cite

Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.

Journal article J Clin Oncol · June 20, 2016 PURPOSE: Tumor screening for Lynch syndrome is recommended in all or most patients with colorectal cancer (CRC). In metastatic CRC, sequencing of RAS/BRAF is necessary to guide clinical management. We hypothesized that a next-generation sequencing (NGS) pa ... Full text Link to item Cite

Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min.

Journal article J Oncol Pract · May 2016 PURPOSE: Oxaliplatin at a dose of 85 mg/m(2) traditionally has been administered over 120 min in the standard FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) regimen. CapeOx (capecitabine plus oxaliplatin), in which the dose of oxaliplatin is ... Full text Link to item Cite

Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study.

Journal article Ann Surg Oncol · April 2016 OBJECTIVE: To analyze the natural history of small asymptomatic pancreatic neuroendocrine tumors (PanNET) and to present a matched comparison between groups who underwent either initial observation or resection. Management approach for small PanNET is unce ... Full text Link to item Cite

Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.

Journal article Clin Cancer Res · February 15, 2016 PURPOSE: Most well-differentiated neuroendocrine tumors (WD-NET) of the enteropancreatic system are low-intermediate grade (G1, G2). Elevated proliferation demonstrated by either a brisk mitotic rate (>20/10 high power fields) or high Ki-67 index (>20%) de ... Full text Link to item Cite

BRAF mutations in patients with large cell neuroendocrine carcinoma of the colon (LCNECC).

Conference Journal of Clinical Oncology · February 1, 2016 567 Background: LCNECC is a rare, poorly differentiated neoplasm with a median survival of 13 months. The cell of origin, genetic mediators and optimal clinical management of LCNECC are unknown. Current guidelines recommend treat ... Full text Cite

Clinical prognostic factors and genomic analysis of ovary metastases (mets) from colorectal cancer (CRC).

Conference Journal of Clinical Oncology · February 1, 2016 564 Background: Ovary mets constitute 5-10% of CRC mets, are associated with poor prognosis, cause morbidity due to disproportionately rapid growth compared with other mets and are less responsive to chemotherapy. The optimal man ... Full text Cite

Next-generation sequencing (NGS) in advanced well differentiated pancreatic neuroendocrine tumors (WD pNETs): A study using MSK-IMPACT.

Conference Journal of Clinical Oncology · February 1, 2016 246 Background: Whole exome sequencing in WD pNETs demonstrated an increased number of mutations in chromatin modeling genes (MEN1, DAXX, and ATRX), and in the mTOR pathway. NGS brings this technology to the clinic but its releva ... Full text Cite

Recurrence rates of resected appendix carcinoid tumors: A 20-year experience at Memorial Sloan Kettering Cancer Center.

Conference Journal of Clinical Oncology · February 1, 2016 221 Background: NETs of the appendix are rare neoplasms most often discovered during incidental appendectomy. Risk of nodal metastases based on single institution series has suggested that appendix carcinoid tumors > 2 cm shou ... Full text Cite

Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.

Journal article Hematol Oncol Clin North Am · February 2016 Pancreatic neuroendocrine tumors are an uncommon tumor type and compose 1% to 2% of all pancreatic neoplasms. They are rarely localized at presentation and are typically diagnosed in the presence of metastatic disease. The management poses a significant ch ... Full text Link to item Cite

Identification of germline genetic mutations in patients with pancreatic cancer.

Journal article Cancer · December 15, 2015 BACKGROUND: Pancreatic adenocarcinoma (PAC) is part of several cancer predisposition syndromes; however, indications for genetic counseling/testing are not well-defined. In the current study, the authors sought to determine mutation prevalence and characte ... Full text Link to item Cite

Characterization of Rectal Cancer in Patients With Lynch Syndrome

Conference International Journal of Radiation Oncology*Biology*Physics · November 2015 Full text Cite

Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.

Journal article Cancer Chemother Pharmacol · June 2015 Neuroendocrine tumors (NETs) are rare tumors that have been increasing in incidence over the last 30 years with no significant changes in survival. As survival of patients with these tumors depends greatly on stage and histology, early diagnosis, classific ... Full text Link to item Cite

Oxaliplatin can be safely infused at a rate of 1mg/m2/min.

Conference Journal of Clinical Oncology · May 20, 2015 Full text Cite

Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.

Journal article J Clin Oncol · May 10, 2015 PURPOSE: There are few effective therapies for pancreatic neuroendocrine tumors (PNETs). Recent placebo-controlled phase III trials of the mammalian target of rapamycin (mTOR) inhibitor everolimus and the vascular endothelial growth factor (VEGF)/platelet- ... Full text Link to item Cite

Simultaneous segmentation and iterative registration method for computing ADC with reduced artifacts from DW-MRI.

Journal article Med Phys · May 2015 PURPOSE: Apparent diffusion coefficient (ADC), derived from diffusion-weighted magnetic resonance images (DW-MRI), measures the motion of water molecules in vivo and can be used to quantify tumor response to therapy. The accurate measurement of ADC can be ... Full text Link to item Cite

Emerging treatments for gastroenteropancreatic neuroendocrine tumors: Use in the Clinic

Journal article Clinical Advances in Hematology and Oncology · May 1, 2015 Cite

New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.

Journal article Clin Adv Hematol Oncol · May 2015 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare, generally indolent neoplasms that can arise throughout the gastrointestinal system. Some GEP-NETs, known as functional, secrete hormones that can lead to a complex of symptoms. Classical car ... Link to item Cite

Successful control of liver metastases from pancreatic solid-pseudopapillary neoplasm (SPN) using hepatic arterial embolization.

Journal article Cardiovasc Intervent Radiol · April 2015 No systemic agents that are known to be effective for the treatment of solid-pseudopapillary neoplasm (SPN) are available. We report the prolonged and sustained control of metastatic pancreatic SPN to the liver using hepatic arterial embolization (HAE), wh ... Full text Link to item Cite

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.

Journal article Clin Cancer Res · March 15, 2015 PURPOSE: BRAF-mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of colorectal cancer with minimal response to selective RAF inhibitors. Preclinical data show that reactivation of EGFR signaling occurs in colorectal tumor cells treated w ... Full text Link to item Cite

Metastatic insulinoma: current molecular and cytotoxic therapeutic approaches for metastatic well-differentiated panNETs.

Journal article J Natl Compr Canc Netw · February 2015 Pancreatic neuroendocrine tumors (panNETs) are a type of neuroendocrine tumor with 5-year overall survival rates of approximately 50% when metastasis is present at diagnosis. Tumor grade, as defined by Ki-67 proliferation index, influences overall survival ... Full text Link to item Cite

Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer.

Conference Journal of Clinical Oncology · January 20, 2015 611 Background: BRAF mutant metastatic colorectal cancer (mCRC) is an aggressive subset of colorectal cancer that exhibits minimal response to selective RAF inhibitors. Preclinical data suggest that epidermal growth factor recept ... Full text Cite

Intensity-modulated radiation therapy (IMRT) in patients with locally advanced pancreatic cancer (LAPC).

Conference Journal of Clinical Oncology · January 20, 2015 377 Background: To assess IMRT safety and evaluate local control and resectability among patients with LAPC treated with induction CT followed by IMRT. Methods: We reviewed records of 134 LAPC patients treated with CT (median dur ... Full text Cite

BRAF mutations in patients with well-differentiated pancreatic neuroendocrine tumors (WD pNETs).

Conference Journal of Clinical Oncology · January 20, 2015 321 Background: Whole exome sequencing in WD pNETs demonstrated an increased number of mutations in genes implicated in chromatin remodeling and in the PI3K/Akt/mTOR pathway. Next-generation sequencing (NGS) allows us to bring th ... Full text Cite

The management of small asymptomatic pancreatic neuroendocrine tumors: A matched case-control study.

Conference Journal of Clinical Oncology · January 20, 2015 239 Background: Overdiagnosis and overtreatment has become an evolving challenge for several cancer sub-types. We hypothesized that a substantial portion of incidentally diagnosed small pancreatic neuroendocrine tumors(PanNET) ar ... Full text Cite

Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.

Journal article Clin Colorectal Cancer · December 2014 BACKGROUND: Heat shock protein 90 (Hsp90) is a cellular chaperone that is required for the maturation and stability of a variety of proteins that play key roles in colon cancer initiation and progression. The primary objective of the current study was to d ... Full text Link to item Cite

Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.

Journal article Pancreas · November 2014 Neuroendocrine tumors (NETs) are a group of tumors originating in various locations, including the gastrointestinal tract, lung, and pancreas. Clinical trial design and disease management of these tumors pose a significant challenge because of the heteroge ... Full text Link to item Cite

A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum.

Journal article Ann Surg Oncol · September 2014 BACKGROUND: High-grade neuroendocrine carcinomas (HGNECs) of the colon and rectum are rare, constituting less than 1 % of colorectal cancers. The purpose of this study was to identify the natural history and oncologic outcomes of this disease, describe the ... Full text Link to item Cite

Chemotherapy and Intensity Modulated Radiation Therapy for Locally Advanced Pancreatic Cancer Achieves Prolonged Survival

Conference International Journal of Radiation Oncology*Biology*Physics · September 2014 Full text Cite

A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.

Journal article Ann Surg · July 2014 BACKGROUND: The role for neoadjuvant systemic therapy in resectable pancreas adenocarcinoma remains undefined. OBJECTIVE: We evaluated the efficacy of gemcitabine and oxaliplatin administered as preoperative therapy in patients with resectable pancreas ade ... Full text Link to item Cite

False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer.

Journal article J Natl Compr Canc Netw · June 2014 Routine monitoring of carcinoembryonic antigen (CEA) levels is standard in patients with resected colorectal cancer (CRC). The incidence of false-positives and the upper limits of false-positive elevations have not been previously well characterized. A sea ... Full text Link to item Cite

Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases.

Conference Am J Surg Pathol · April 2014 BACKGROUND: In the pancreas, poorly differentiated neuroendocrine carcinomas include small cell carcinoma and large cell neuroendocrine carcinoma and are rare; data regarding their pathologic and clinical features are very limited. DESIGN: A total of 107 p ... Full text Link to item Cite

Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer.

Journal article J Natl Compr Canc Netw · April 2014 Standard therapy for locally advanced rectal cancer (LARC) is preoperative chemoradiotherapy and postoperative chemotherapy. At Memorial Sloan-Kettering Cancer Center (MSKCC) the authors began offering FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) a ... Full text Link to item Cite

Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors.

Journal article J Gastrointest Surg · March 2014 BACKGROUND: Duodenal neuroendocrine tumors are rare and few studies exist to guide surgical management. This study identifies factors associated with recurrence after resection. METHODS: A retrospective, single institution review was performed between 1983 ... Full text Link to item Cite

Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.

Journal article J Clin Oncol · February 20, 2014 PURPOSE: Although neoadjuvant chemoradiotherapy achieves low local recurrence rates in clinical stages II to III rectal cancer, it delays administration of optimal chemotherapy. We evaluated preoperative infusional fluorouracil, leucovorin, and oxaliplatin ... Full text Link to item Cite

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

Journal article J Hepatol · February 2014 BACKGROUND & AIMS: IGF-IR is implicated in hepatic carcinogenesis. This and preliminary evidence of biological activity of anti-IGF-1R monoclonal antibody cixutumumab in phase I trials prompted this phase II study. METHODS: Patients with advanced HCC, Chil ... Full text Link to item Cite

Response rates to hepatic arterial infusion (HAI) pump therapy in patients with metastatic colorectal cancer liver metastases (mCRC LM) after progression on all standard chemotherapies.

Conference Journal of Clinical Oncology · January 20, 2014 597 Background: To evaluate the overall response rate of HAI with floxuridine (FUDR) in the refractory setting in patients with mCRC LM. Methods: After obtaining an IRB waiver a computerized search was performed for patients with ... Full text Cite

False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer.

Conference Journal of Clinical Oncology · January 20, 2014 403 Background: Routine monitoring of carcinoembryonic antigen (CEA) is standard practice in patients with a history of resected colorectal cancer. While it is known that false positive elevations of CEA can occur, the incidence ... Full text Cite

Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases.

Journal article J Vasc Interv Radiol · January 2014 PURPOSE: To identify factors affecting periprocedural morbidity and mortality and long-term survival following hepatic artery embolization (HAE) of hepatic neuroendocrine tumor (NET) metastases. MATERIALS AND METHODS: This single-center, institutional revi ... Full text Link to item Cite

Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer.

Journal article Clin Colorectal Cancer · September 2013 BACKGROUND: Studies indicate that the incidence of young women diagnosed with colorectal cancer is rising, thus there is an increasing number of female colorectal cancer survivors of premenopausal and child-bearing age. Adjuvant FOLFOX (5-fluorouracil, leu ... Full text Link to item Cite

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.

Journal article Br J Cancer · August 20, 2013 BACKGROUND: This study evaluated the addition of sorafenib to gemcitabine and cisplatin in biliary adenocarcinoma first-line therapy. METHODS: Patients with advanced biliary adenocarcinomas received gemcitabine 1000 mg m(-2) and cisplatin 25 mg m(-2) on a ... Full text Link to item Cite

A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients.

Conference J Palliat Med · June 2013 BACKGROUND: Cardiopulmonary resuscitation (CPR) is an important advance directive (AD) topic in patients with progressive cancer; however such discussions are challenging. OBJECTIVE: This study investigates whether video educational information about CPR e ... Full text Link to item Cite

Consensus guidelines for the management and treatment of neuroendocrine tumors.

Journal article Pancreas · May 2013 Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The ... Full text Link to item Cite

Pancreatic neuroendocrine paraneoplastic optic neuropathy: confirmation with antibody to optic nerve and hepatic metastasis.

Journal article J Neuroophthalmol · March 2013 A 68-year-old woman presented with bilateral visual loss as the only clinical manifestation of an occult pancreatic nonsecretory neuroendocrine tumor (NET). The suspected diagnosis of paraneoplastic optic neuropathy was confirmed using immunofluorescence a ... Full text Link to item Cite

Induction chemotherapy followed by chemoradiotherapy and total mesenteric excision for locally advanced rectal cancer with resectable metastases.

Conference Journal of Clinical Oncology · February 1, 2013 526 Background: Optimal management of patients with locally advanced rectal cancer (LARC) and synchronous, resectable metastases remains controversial and treatment decisions benefit from a multidisciplinary approach. To better c ... Full text Cite

Characterization of rectal cancer in patients with Lynch syndrome.

Conference Journal of Clinical Oncology · February 1, 2013 350 Background: Lynch syndrome (LS), resulting from a germline mutation in a DNA mismatch repair (MMR) gene, is associated with ~70% lifetime colorectal cancer (CRC) risk. Although LS-associated colon cancer is associated with bo ... Full text Cite

The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas.

Journal article Semin Oncol · February 2013 Extrapulmonary high-grade neuroendocrine carcinomas (HGNECs) are rare but aggressive tumors that can be found throughout the body but are most commonly located in the gastrointestinal (GI) and the genitourinary tracts. They also have been described in the ... Full text Link to item Cite

Goblet cell carcinoid neoplasm of the appendix: clinical and CT features.

Journal article Eur J Radiol · January 2013 PURPOSE: To describe the clinical and CT imaging features of goblet cell carcinoid (GCC) neoplasm of the appendix. METHODS AND MATERIALS: A computer search of pathology and radiology records over a 19-year period at our two institutions was performed using ... Full text Link to item Cite

Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned.

Journal article Oncologist · 2013 In the past 3 years, we have witnessed the completion of four randomized phase III studies in neuroendocrine tumors and the approval of two new drugs, everolimus and sunitinib, for the treatment of patients with well-differentiated pancreatic neuroendocrin ... Full text Link to item Cite

In reply.

Journal article Oncologist · 2013 Neuroendocrine tumors exhibit diverse clinical outcomes, and several recent studies have demonstrated that tumor histology, which incorporates assessments of tumor differentiation, tumor grade, mitotic rate, and proliferative index, can be associated with ... Full text Link to item Cite

A case report of a patient with advanced acinar cell carcinoma of the pancreas: long-term survival with regional, systemic and targeted therapy.

Journal article Tumori · 2013 Acinar cell carcinoma of the pancreas is an uncommon malignancy for which there are no prospective, randomized data to guide therapy. We describe the clinical course and management of a patient with advanced pancreatic acinar cell carcinoma who is alive se ... Full text Link to item Cite

Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors.

Journal article Cancer · October 15, 2012 BACKGROUND: Dermatologic adverse events stemming from anticancer therapies have become an increasingly frequent clinical problem. Inhibitors of mammalian target of rapamycin (mTOR), such as temsirolimus and everolimus, have been associated with a high rate ... Full text Link to item Cite

A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.

Journal article Cancer · October 1, 2012 BACKGROUND: Neuroendocrine tumor (NET) cell lines frequently express both insulin-like growth factor (IGF) ligand and the cognate IGF-1 receptor (IGF-1R) and, as such, potentially depend on the activation of IGF-1R and its downstream effectors for growth a ... Full text Link to item Cite

Unusual Tumors of the Colon, Rectum, And Anus

Book section · September 20, 2012 Cancers of the colon, rectum, and anus account for more than 150,000 new cases in the United States each year. The overwhelming majority (approximately 97%) of these are adenocarcinomas of the colon or rectum. Of the 3% that make up the uncommon tumors, ap ... Full text Cite

Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?

Journal article Curr Oncol Rep · June 2012 Well-differentiated neuroendocrine tumors (NETs) can be subdivided into carcinoid and pancreatic NETs (panNETs). Recently, two therapies have been FDA approved for progressive well-differentiated pancreatic NETs but have not been submitted for use in carci ... Full text Link to item Cite

Systemic therapy for advanced pancreatic neuroendocrine tumors: an update.

Journal article J Natl Compr Canc Netw · June 1, 2012 Well-differentiated neuroendocrine tumors (NETs) can be subdivided into carcinoid and pancreatic NETs (pancNETs). Although these tumors share many morphologic and clinical characteristics, carcinoid tumors appear to be far less sensitive to therapeutic age ... Full text Link to item Cite

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

Journal article Clin Colorectal Cancer · June 2012 BACKGROUND: Cetuximab (C), alone or with irinotecan, demonstrates activity in irinotecan-refractory colorectal cancer (CRC). Activity of 5-fluorouracil (5-FU), leucovorin (L), and bevacizumab (B), and preliminary data of cetuximab + bevacizumab, and toxici ... Full text Link to item Cite

Updates on well-differentiated neuroendocrine tumors

Journal article Salud I Ciencia · March 1, 2012 Well-differentiated neuroendocrine tumors (NETs) are uncommon malignancies consisting of both carcinoid and pancreatic neuroendocrine tumors (pNETs). These tumors are usually associated with metastasis when diagnosed. Although prolonged survival is common, ... Cite

Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).

Conference Journal of Clinical Oncology · February 1, 2012 260 Background: Recent placebo-controlled phase III trials of the mTOR inhibitor everolimus and the VEGF/ PDGF receptor inhibitor sunitinib in PNET noted improved progression-free survival (PFS). However, objective response rates ... Full text Cite

The efficacy of capecitabine and temozolomide for the treatment of metastatic neuroendocrine tumors: Memorial Sloan-Kettering Cancer Center experience.

Conference Journal of Clinical Oncology · February 1, 2012 363 Background: Emerging literature has suggested the benefit of capecitabine/temozolomide (C/T) therapy in metastatic pancreatic NETs (pNETs) as first line therapy. We conducted a retrospective analysis of the efficacy of (C/T) ... Full text Cite

Phase II study of ganetespib, an hsp-90 inhibitor, in patients with refractory metastatic colorectal cancer.

Conference Journal of Clinical Oncology · February 1, 2012 467 Background: To evaluate the safety and efficacy of ganetespib, a heat shock protein 90 (Hsp90) inhibitor, as monotherapy in patients with refractory metastatic colorectal cancer. Methods: A phase II study ut ... Full text Cite

Outcomes of patients undergoing percutaneous biliary drainage to reduce bilirubin for administration of chemotherapy.

Journal article J Vasc Interv Radiol · January 2012 PURPOSE: To describe outcomes in patients undergoing percutaneous biliary drainage to reduce total serum bilirubin level for administration of chemotherapy. MATERIALS AND METHODS: A total of 647 consecutive patients underwent percutaneous biliary drainage ... Full text Link to item Cite

Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision.

Journal article Ann Surg Oncol · December 2011 BACKGROUND: Neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy is typically recommended for patients with locally advanced rectal cancer. Patients with pathologically node-negative tumors have an improved prognosis, but recurrence pat ... Full text Link to item Cite

Intensity Modulated Radiation Therapy for Locally Advanced Pancreatic Cancer Achieves High Rate of R0 Resection

Conference International Journal of Radiation Oncology*Biology*Physics · October 2011 Full text Cite

Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document.

Journal article Gynecol Oncol · July 2011 OBJECTIVE: Neuroendocrine tumors of the gynecologic tract are rare, and pose a significant clinical challenge because of the tumor heterogeneity and lack of standardized guidelines for treatment. This manuscript summarizes the available literature concerni ... Full text Link to item Cite

Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer.

Journal article Drugs · May 7, 2011 Well differentiated neuroendocrine tumours (WDNET) are a diverse group of cancers that are often advanced at the time of diagnosis and generally do not respond significantly to traditional chemotherapy. A number of intriguing therapeutic targets have emerg ... Full text Link to item Cite

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.

Journal article Cancer Metastasis Rev · March 2011 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show limited sensitivity to cytotoxic agents, requiring the search for novel therapies. Recently, data from a phase III trial demonstrated that sunitinib produces a clinically significant improvement ... Full text Link to item Cite

Incidence of FOLFOX induced amenorrhea in women age 40 and younger with colorectal cancer.

Conference Journal of Clinical Oncology · February 1, 2011 567 Background: The effects of oxaliplatin-based chemotherapy on female fertility are largely unknown. Studies have indicated that the incidence of young women diagnosed with colorectal cancer is on the rise, thus there is an inc ... Full text Cite

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.

Journal article J Clin Oncol · September 20, 2010 PURPOSE: To evaluate the safety and efficacy of IMC-A12, a human monoclonal antibody (mAb) that blocks insulin-like growth factor receptor-1 (IGF-1R), as monotherapy or in combination with cetuximab in patients with metastatic refractory anti-epidermal gro ... Full text Link to item Cite

Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liver.

Journal article Cardiovasc Intervent Radiol · June 2010 Hepatic encephalopathy is considered a contraindication to hepatic artery embolization. We describe a patient with a well-differentiated neuroendocrine tumor metastatic to the liver with refractory hepatic encephalopathy and normal liver function tests. Th ... Full text Link to item Cite

Adenocarcinoma of unknown primary in a 20-year-old African American male.

Journal article Clin Genitourin Cancer · August 2009 A 20-year-old African American male presented with a history of left flank pain and passing of light pink urine. Medical history included sickle cell trait. Urine analysis was positive for protein and blood. Metabolic profile, autoantibody screen, and comp ... Full text Link to item Cite

Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors.

Journal article Nat Clin Pract Oncol · March 2009 Well-differentiated neuroendocrine tumors (NETs), which are also referred to as well-differentiated endocrine carcinoma according to WHO terminology, are usually slow-growing cancers, even when they exhibit gross local invasion and/or metastases. The survi ... Full text Link to item Cite

Estimating object depth using a vertical gradient metal detector

Conference Proceedings of SPIE the International Society for Optical Engineering · June 2, 2008 Object depth is a simple characteristic that can indicate an object's type. Popular instruments like radar, metal detectors, and magnetometers are often used to detect the presence of a subsurface object. The next question is often, "How deep is it?" Deter ... Full text Cite

Targeted strategies in the treatment of metastatic colon cancer.

Journal article J Natl Compr Canc Netw · October 2007 Advances in the understanding of tumor biology have led to the identification of important cellular processes involved in the pathogenesis of colon cancer. Drugs that interfere with these critical pathways are known as targeted agents. The goal of these th ... Full text Link to item Cite

Bevacizumab 5 mg/kg can be infused safely over 10 minutes.

Journal article J Clin Oncol · July 1, 2007 PURPOSE: Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor. As a result of concerns for potential infusion-related hypersensitivity reactions (HSRs), initial phase I trials used a 90-, 60-, 30-minute initial inf ... Full text Link to item Cite

Targeted therapy for metastatic colorectal cancer: Current challenges and future directions

Journal article Current Colorectal Cancer Reports · July 1, 2007 Progress in understanding tumor biology has led to the identification of a number of candidate molecules that are potential targets for the medical treatment of cancer. Drugs that impede these molecules are labeled targeted therapies. The goal of these dru ... Full text Cite

Bevacizumab 5mg/kg can be safely infused over 10 minutes

Conference JOURNAL OF CLINICAL ONCOLOGY · June 20, 2007 Link to item Cite

Baseline signature data for multisensor (EM/GPR) algorithmic development

Conference Proceedings of SPIE the International Society for Optical Engineering · December 20, 2004 I A government-funded effort was initiated to further develop algorithms based on the technology used in the U.S. Army's latest handheld standoff mine detection system (HSTAMIDS). To this end, a complete multisensor (EM/GPR) baseline signature data set was ... Full text Cite

Clutter removal processing for improved mine detection using a frequency stepped GPR

Conference Proceedings of SPIE the International Society for Optical Engineering · December 20, 2004 The assumption is that removal of elements of clutter from the frequency stepped ground penetration radar (GPR) signal data will improve the performance of any detection algorithms. Clutter comes in the form of internal system interference, cross-coupling ... Full text Cite

Effects of soil magnetic susceptibility and electrical conductivity on electromagnetic detection of landmines

Conference Proceedings of SPIE the International Society for Optical Engineering · December 20, 2004 Newer detectors are growing in capability to discriminate those signals measured over mines from those signals that can be causally related to local variations in the soil. Monitoring and measuring the key properties governing these local variations are be ... Full text Cite

Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma.

Journal article Anticancer Drugs · June 2004 Hepatocellular carcinoma (HCC) is common worldwide and frequently fatal. Despite the availability of potentially curative therapies for localized HCC, most patients have unresectable tumor, either at presentation or recurrence. We reviewed 18 randomized tr ... Full text Link to item Cite

A statistical approach to landmine detection using broadband electromagnetic induction data

Journal article IEEE Transactions on Geoscience and Remote Sensing · April 1, 2002 The response of time-domain electromagnetic induction (EMI) sensors, which have been used almost exclusively for landmine detection, is related to the amount of metal present in the object and its distance from the sensor. Unluckily, there is often a signi ... Full text Cite

Improving detection of low-metallic content landmines using EMI data

Conference International Geoscience and Remote Sensing Symposium IGARSS · December 1, 2000 EMI, or metal detector, sensors are used extensively to detect landmines. There is often a significant amount of metallic clutter present in the environment, thus EMI sensors that utilize traditional detection algorithms based solely on metal content suffe ... Cite

Improved detection of low-metallic content landmines using EMI data

Conference Proceedings of SPIE - The International Society for Optical Engineering · 2000 EMI sensors are used extensively to detect landmines, and operate by detecting the metal that is present in mines. However, mines vary in their construction from metal-cased varieties with a large mass of metal to plastic-cased varieties with minute amount ... Full text Link to item Cite

Improved detection of low-metallic content landmines using EMI data

Conference Proceedings of SPIE the International Society for Optical Engineering · January 1, 2000 EMI sensors are used extensively to detect landmines, and operate by detecting the metal that is present in mines. However, mines vary in their construction from metal-cased varieties with a large mass of metal to plastic-cased varieties with minute amount ... Cite

Statistical signal processing techniques for the detection of low-metal landmines using EMI and GPR sensors (topic area: E.1)

Conference International Geoscience and Remote Sensing Symposium IGARSS · December 1, 1999 The Joint UXO Coordination Office (JUXOCO) at Ft. Belvoir, VA is sponsoring a series of experiments designed to establish a performance baseline for a variety of sensors. The purpose of these experiments is to determine if advanced algorithms are useful fo ... Cite

Operational standoff mine detection: its technology and application

Conference Proceedings of SPIE the International Society for Optical Engineering · December 1, 1997 This paper explores the application of standoff vehicular mounted mine detection technologies. These technologies could support a fieldable standoff mine detection system for the digitized battlefield.In the rapidly evolving countermine field, the standoff ... Cite

Focused array radar for real-time imaging and detection

Conference Proceedings of SPIE the International Society for Optical Engineering · January 1, 1996 The Focused Array Radar (FAR) is a unique time-domain radar system which uses adjustable time delayed signals in a wide multi-element array which focuses transmitted and received signals to detect targets in lossy soil. By making use of specially-designed ... Cite

Multisensor data fusion for mine detection

Conference Proceedings of SPIE the International Society for Optical Engineering · December 1, 1990 This paper demonstrates the advantages of applying multisensor data fusion techniques for the mine detection and classification problem. It has long been recognized that no single sensor technique is adequate for the detection and classification of the wid ... Cite